Appropriate Eye Drop Antibiotics for Bacterial Conjunctivitis

First-Line Options

• Gatifloxacin 0.5% ophthalmic solution is a fourth-generation fluoroquinolone with better coverage of gram-positive pathogens than earlier generations, according to the American Academy of Ophthalmology 1, 2

Treatment Algorithm

Severe Cases or Treatment Failures

• For suspected MRSA conjunctivitis, consider vancomycin as fluoroquinolones are generally poorly effective against MRSA ocular isolates, as recommended by the American Academy of Ophthalmology 2, 3
• For resistant Pseudomonas aeruginosa, topical colistin 0.19% may be considered, based on guidelines from the American Academy of Ophthalmology 3

Efficacy Considerations

• Topical antibiotics are associated with higher remission rates compared to placebo, with a relative risk for clinical remission of 1.36 (95% CI, 1.15-1.61), according to the Infectious Diseases Society of America 4

Important Caveats

• Increasing resistance to fluoroquinolones has been observed, with risk factors including recent fluoroquinolone use, hospitalization, age, and recent ocular surgery, as reported by the American Academy of Ophthalmology 3, 5
• Methicillin resistance has been found in 42% of Staphylococcal isolates, with high concurrent resistance to fluoroquinolones, according to the American Academy of Ophthalmology 3, 5

Special Populations

• For neonates with chlamydial conjunctivitis, erythromycin is associated with high clinical (96%) and microbiological cure rates (97%), based on recommendations from the American Academy of Pediatrics 4
• For gonococcal conjunctivitis, systemic antibiotic therapy is necessary in addition to topical treatment, as recommended by the Centers for Disease Control and Prevention 4, 5

Bacterial Conjunctivitis Treatment Guidelines

Primary Treatment Recommendations

• The American Academy of Ophthalmology recommends moxifloxacin 0.5% as a first-line therapy with demonstrated superior gram-positive coverage compared to earlier fluoroquinolones 6
• Besifloxacin 0.6% demonstrates better coverage against ciprofloxacin- and methicillin-resistant staphylococci than moxifloxacin 7

Critical Resistance Considerations

• The Centers for Disease Control and Prevention advises against using fluoroquinolones if MRSA is suspected, as they are generally poorly effective against MRSA ocular isolates 6
• Methicillin resistance is found in 42% of Staphylococcal isolates with high concurrent fluoroquinolone resistance 6

Special Pathogen Considerations

• Moraxella keratitis requires prolonged treatment duration (mean 41.9 days) despite susceptibility to fluoroquinolones 6